Journals / Mersin Üniversitesi Sağlık Bilimleri Dergisi / 2019 / Cilt: 12 - Sayı: 2

Development of experimental schizophrenia models and evaluation of schizophrenia symptoms with tests

Deneysel şizofreni modellerinin oluşturulması ve deneysel yöntemlerle şizofreni belirtilerinin değerlendirilmesi

Pages
351–359
Publication Date
2019-08-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In order to understand the basics of this disease, which is formed by genetic, developmental and chemical models, and to develop new treatments, we reached a conclusion that more advanced experimental animal models should be developed and used in more comprehensive studies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Schizophrenia, a common and serious psychiatric disorder, affects 0.5% to 1% of the world population.
📊
Key Findings & Data:Schizophrenia is a neurodevelopmental disorder with complex clinical findings due to various symptoms.
💡
Conclusion & Impact:In order to understand the basics of this disease, which is formed by genetic, developmental and chemical models, and to develop new treatments, we reached a conclusion that more advanced experimental animal models should be developed and used in more comprehensive studies.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Bellek · deneysel hayvan modelleri · fizyopatoloji

Abstract

Schizophrenia, a common and serious psychiatric disorder, affects 0.5% to 1% of the world population. Schizophrenia is a neurodevelopmental disorder with complex clinical findings due to various symptoms. While the etiology of schizophrenia is unknown, it is thought that chemicals in the brain, structural differences and genes have effects on the disease; environmental, psychological and social factors are thought to play a role in the pathogenesis. The development of experimental animal models allows for better understanding of the physiopathology and neurobiological bases of this disease which cannot be modeled in humans. As different experimental methods, genes such as calcineurin and neuregulin in genetic models; prenatal stress in developmental models; drugs such as dopaminergic agonist in pharmaceutical and chemical models; hippocampal lesion is used in the production of experimental animal models. Low energy, lack of motivation, delusion, hallucinations, inability to understand and learning, memory attenuation etc. are known as symptoms of schizophrenia. In experimental animal models produced by different methods, behavioral test models are used to determine which symptoms occur. Among these test methods, prepulse inhibition and new object recognition tests are mostly used. The new object recognition test is related to the cognitive symptoms of schizophrenia while the prepulse inhibition test is related to its positive symptoms. In order to understand the basics of this disease, which is formed by genetic, developmental and chemical models, and to develop new treatments, we reached a conclusion that more advanced experimental animal models should be developed and used in more comprehensive studies.

Özet

Yaygın ve ciddi bir psikiyatrik hastalık olan şizofreni, dünya nüfusunun %0.5-%1’ini etkilemektedir. Şizofreni çeşitli semptomlarla seyretmesi nedeniyle kompleks klinik bulguları olan nörogelişimsel bir bozukluktur. Etiyolojisi tam olarak bilinemeyen şizofrenin gelişiminde beyindeki kimyasalların, yapısal farklılıkların ve genlerin etkisi olduğu düşünülürken; patogenezinde çevresel, psikolojik ve sosyal etkenlerin rolü olduğu düşünülmektedir. Deneysel hayvan modellerinin geliştirilmesi, insanlarda modellenemeyen bu hastalığın fizyopatolojisini ve nörobiyolojik temellerinin anlaşılmasına imkân sağlamaktadır. Deneysel yöntem olarak kalsineurin, neuregulin gibi genler genetik modellerde; prenatal stres gelişimsel modellerde; dopaminerjik agonist gibi ilaçlar ilaç ve kimyasal modellerde; hipokampal lezyon neonatal hipokampüs lezyon modellerinde deneysel hayvan modelleri oluşturulmasında kullanılmaktadır. Düşük enerji, motivasyon eksikliği, delüzyon, halüsinasyon, anlamada ve öğrenmede yetersizlik, bellekte zayıflama vb. şizofreninin bilinen semptomlarındandır. Değişik yöntemlerle oluşturulan deneysel hayvan modellerinde hangi semptomun ortaya çıktığını belirlemek için davranışsal test yöntemleri kullanılmaktadır. Bu test yöntemlerinden prepulse inhibisyon ve yeni obje tanıma testleri çoğunlukla kullanılmaktadır. Yeni obje tanıma testi şizofreninin kognitif semptomlarıyla, prepulse inhibisyon testi ise pozitif semptomlarıyla ilgilidir. Genetik, gelişimsel ve kimyasal modellerle oluşturulan bu hastalığın temellerini kavrayabilmek ve yeni tedaviler geliştirebilmek için deney hayvanı modellerinin geliştirilmesi ve daha geniş çaplı çalışmalarda kullanılması gerektiği sonucuna varılmıştır.

🔖

Cite This Article

ÖZKUL, T., GÖLGELİ, A. (2019). Development of experimental schizophrenia models and evaluation of schizophrenia symptoms with tests. Mersin Üniversitesi Sağlık Bilimleri Dergisi, Cilt: 12 - Sayı: 2, 351–359. https://ajindex.com/articles/92816

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Tamminga CA, Holcomb HH. Phenotype of schizophrenia: a review and formulation. Mol Psychiatry 2005;10:27–39.
  2. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT. Neurobiology of schizophrenia. Neuron 2006;1:139-153. World Health Organization Schizophrenia 2016.
  3. Göktalay G., Aktaş Ö., Kayır H. Turkiye Klinikleri J Pharmacol-Special Topics. 2016;4(1):53-60.
  4. Hay A, Byers A, Sereno M, Basra MK, Dutta S. Asenapine versus placebo for schizophrenia. Cochrane Database Syst Rev. 2015 Nov 24;(11):CD011458. Perry W, Geyer MA, Braff DL: Sensorimotor gating and thought disturbance measured in close temporal proximity in schizophrenic patients. Arch Gen Psychiatry. 1999;56:277-281.
  5. Ural C, Öncü F, Belli H, Soysal H. Adli psikiyatrik süreç içindeki şizofreni hastalarının şiddet davranışı değişkenleri: bir olgu kontrol çalışması. Türk Psikiyatri Dergisi. 2013;24:17-24.
  6. Mouri A, Nagai T, Ibi D, Yamada K. Animal models of schizophrenia for molecular and pharmacological intervention and potential candidate molecules. Neurobiol Dis.2013;53:61-74.
  7. Farrell MS, Werge T, Sklar P, Owen MJ, Ophoff RA, O’Donovan MC, Corvin A, Cichon S, Sullivan PF. Evaluating historical candidate genes for schizophrenia. Mol Psychiatry. 2015;1-8.
  8. Chubb JE, Bradshaw NJ, Soares DC, Porteous DJ, Millar JK. The DISC locus in psychiatric illness. Mol Psychiatry. 2008;13(1):36-64.
  9. Merelo V, Durand D, Lescallette AR, Vrana KE, Hong LE, Faghihi MA, Bellon A. Associating schizophrenia, long non-coding RNAs and neurostructural dynamics. Front Mol Neurosci. 2015;8:57. Ahmed AO, Mantini AM, Fridberg DJ, Buckley PF. Brain-derived neurotrophic factor (BDNF) and neurocognitive deficits in people with schizophrenia: a meta-analysis. Psychiatry Res. 2015;226(1):1-13. Negron‑Oyarzo et al. Schizophrenia and reelin: a model based on prenatal stress to study epigenetics, brain development and behavior. Biol Res. 2016;49:16. Le Strat Y, Ramoz N, Gorwood P. The role of genes involved in neuroplasticity and neurogenesis in the observation of a gene-environment interaction (GxE) in schizophrenia. Current Molecular Medicine. 2009;4:506-518.
  10. Williams N, O’Donovan M, Owen M. Is the dysbindin gene (DTNBP1) a susceptibility gene for schizophrenia? Schizophr Bull. 2005;31:800-805.
  11. Talbot K, Eidem WL, Tinsley CL, Benson MA, Thompson EW, Smith RJ, et al. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. The Journal of clinical investigation. 2004;113:1353-1363. Weickert